
Benzinga Pro data, Fulcrum Therapeutics (NASDAQ:FULC) reported Q1 sales of $2.59 million. Earnings fell to a loss of $25.93 million, resulting in a 10.41% decrease from last quarter. Fulcrum Therapeutics collected $5.06 million in revenue during Q4, but reported earnings showed a $23.48 million loss.